Safety and Efficacy of Tissue Engineered Endothelial Keratoplasty
Recruiting
Phase 1
Interventional Study
Mild to Moderate Corneal Endothelial Decompensation
Bullous Keratopathy
Fuchs' Endothelial Dystrophy
Post-surgical Corneal Decompensation (Irreversible)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 21 – 80
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 30 (estimated)
- Sponsor
- Singapore Eye Research Institute · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Assessment of safety and efficacy of tissue-engineered corneal endothelial graft material generated using cultured human corneal endothelial cells for tissue-engineered endothelial keratoplasty (TE-EK).
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Patients who have mild to moderate corneal endothelial decompensation or bullous keratopathy, but with minimal corneal stromal scarring resulting from a variety of conditions including:
* Fuchs' endothelial dystrophy
* Post-surgical corneal decompensation (irreversible) - all f…
Contacts